Elizabeth Olson Hexner, MD, MSTR
Associate Professor of Medicine (Hematology-Oncology) at the Hospital of the University of Pennsylvania
Department: Medicine
Contact information
Division of Hematology Oncology
Perelman Center for Advanced Medicine
12th Floor, South Pavilion
Office #12-151
3400 Civic Center Boulevard
Philadelphia, PA 19104
Perelman Center for Advanced Medicine
12th Floor, South Pavilion
Office #12-151
3400 Civic Center Boulevard
Philadelphia, PA 19104
Office: 215-614-1847
Fax: 215-615-5888
Fax: 215-615-5888
Links
The Cell and Gene Therapy Toolkit for Junior Faculty
Penn Center for Myeloproliferative Neoplasms
The Cell and Gene Therapy Toolkit for Junior Faculty
Penn Center for Myeloproliferative Neoplasms
Education:
A.B. (French/Comparative Area Studies)
Duke University, 1992.
(Premedical Studies)
Harvard University Extension School, 1994.
M.D. (Medicine)
Columbia College of Physicians and Surgeons, 1999.
M.S.T.R. (Translational Research)
University of Pennsylvania, 2009.
Permanent linkA.B. (French/Comparative Area Studies)
Duke University, 1992.
(Premedical Studies)
Harvard University Extension School, 1994.
M.D. (Medicine)
Columbia College of Physicians and Surgeons, 1999.
M.S.T.R. (Translational Research)
University of Pennsylvania, 2009.
Description of Research Expertise
Genetically modified T Cell TherapiesCAR T cells
Cellular therapy
Blood and Marrow Transplantation
Myeloproliferative Neoplasms
Umbilical Cord Blood Transplantation
Selected Publications
Salit RB, Hexner EO, Gagelmann N, Kröger N, McLornan DP, Jain T, Gupta V, Hobbs GS, Tamari R, Robin M, Scott B, Saber W: Defining remission following hematopoietic cell transplant for myelofibrosis: an international expert panel consensus. Leukemia Oct 2025.Aznar MA, Good CR, Barber-Rotenberg JS, Agarwal S, Wilson W, Watts A, Zhang Z, Gonzales D, Donahue G, Hwang WT, Rennels AK, Rech AJ, Kuramitsu S, Huang H, Glastad KM, Alexander KA, Plesa G, Dowd E, Brennan A, Siegel DL, Tanyi J, Haas A, Torigian DA, Nadolski G, Gonzalez VE, Hexner EO, Fraietta JA, Jadlowsky JK, Young RM, Berger SL, June CH, O'Hara MH: Clinical and molecular dissection of CAR T cell resistance in pancreatic cancer. Cell Rep Med Sep 2025.
Akahoshi Y, Portelli J, Katsivelos N, Louloudis IE, Aguayo-Hiraldo PI, Ayuk FA, Chanswangphuwana C, Choe HK, Eder M, Etra AM, Hexner EO, Kitko CL, Kraus S, Merli P, Olson TS, Pasic I, Qayed M, Reshef R, Schechter-Finkelstein T, Marx J, Ullrich E, Vasova I, Weber D, Wölfl M, Zeiser R, Baez J, Eng GW, Gleich S, Kowalyk SM, Morales G, Spyrou N, Young R, DeFilipp Z, Hogan WJ, Nakamura R, Levine JE, Ferrara JLM: The MAGIC Composite Response: A Novel Endpoint Integrating Clinical and Biomarker Parameters for Acute GVHD. Blood Adv. Aug 2025.
Svoboda J, Hexner E, June CH: Enhanced CAR T-Cell Therapy for Relapsed Lymphoma. Reply. N Engl J Med Aug 2025.
Akahoshi Y, Inamoto Y, Spyrou N, Nakasone H, Diniz M, Asada N, Ayuk FA, Choe HK, Doki N, Eto T, Etra AM, Hexner EO, Hiramoto N, Hogan WJ, Holler EPDm, Kataoka K, Kawakita T, Tanaka M, Tanaka T, Uchida N, Vasova I, Yoshihara S, Ishimaru F, Fukuda T, Chen YB, Kanda J, Nakamura R, Atsuta Y, Ferrara JLM, Kanda Y, Levine JE, Teshima T. : Refinement of Day 28 Treatment Response Criteria for Acute GVHD: A Collaboration Study of the JSTCT and MAGIC. Blood Adv. Jul 2025.
Bagley SJ, Desai AS, Fraietta JA, Silverbush D, Chafamo D, Freeburg NF, Gopikrishna GK, Rech AJ, Nabavizadeh A, Bagley LJ, Park J, Jarocha D, Martins R, Sarmiento N, Maloney E, Lledo L, Stein C, Marshall A, Leskowitz RM, Jadlowsky JK, Mackey S, Christensen S, Oner BS, Plesa G, Brennan A, Gonzalez V, Chen F, Barrett D, Colbourn R, Nasrallah MP, Mourelatos Z, Hwang WT, Alanio C, Siegel DL, June CH, Hexner EO, Binder ZA, O'Rourke DM.: Intracerebroventricular bivalent CAR T cells targeting EGFR and IL-13Rα2 in recurrent glioblastoma: a phase 1 trial. Nat Med Jun 2025.
Verschraegen CF, Hashibe M, Neill US, Pirl W, Hexner EO, O'Connell A; NASDC Consortium.: NCI Awardee Skills Development Consortium (NASDC): a Successful Novel Educational Effort to Maintain Early Academic Competitiveness: PART 1-Overview of the NASDC Coordinating Center. J Cancer Educ Jun 2025.
Svoboda J, Landsburg DJ, Gerson J, Nasta SD, Barta SK, Chong EA, Cook M, Frey NV, Shea J, Cervini A, Marshall A, Four M, Davis MM, Jadlowsky JK, Chew A, Pequignot E, Gonzalez V, Noll JH, Paruzzo L, Rojas-Levine J, Plesa G, Scholler J, Siegel DL, Levine BL, Porter DL, Ghassemi S, Ruella M, Rech A, Leskowitz RM, Fraietta JA, Hwang WT, Hexner E, Schuster SJ, June CH: Enhanced CAR T-Cell Therapy for Lymphoma after Previous Failure. N Engl J May 2025.
Hexner EO, DeFilipp Z.: Update in GVHD Prophylaxis: Novel Pharmacologic and Graft Manipulation Strategies. Am J Hematol May 2025.
Rowe, M., Babushok, D., Carroll, M., Carulli, A., Frey, N., Gill, S., Hexner, E., Hirsh, R., Hossain, N., Lai, C., Loren, A., Luger, S., Maillard, I., McCurdy, S., Matthews, A., Martin, M.E., Paralkar, V.R., Perl, A., Porter, D., Pratz, K., Stadtmauer, E. and Bruno, X.J. : Tumor Lysis Syndrome in Acute Myeloid Leukemia Patients Treated With a Venetoclax Based Regimen. Eur J Haematol Apr 2025.